A Prospective Study Evaluating the Clinical Outcomes of Ventral or Inguinal Hernias Treated Robotically With OviTex® Reinforced Tissue Matrix

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is designed to evaluate the post-operative complications and hernia recurrence following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: t
View:

• Subject suffers from a ventral or inguinal hernia that requires surgical repair with the use of an implant to reinforce or replace weakened or missing tissue.

• The patient is scheduled for an elective robotic approach with the use of OviTex LPR, OviTex Core Permanent, or OviTex 1S Permanent.

• The size of the implant needed for repair is expected to be less than or equal to 15 x 25 cm for OviTex LPR and 25 x 40 cm for OviTex Core Permanent and OviTex 1S Permanent.

• Subject meets CDC/SSI Wound Classification Class I (Clean), Class II (Clean-Contaminated) or Class III (Contaminated) criteria.

• Subject is willing and able to sign an informed consent for the study and has signed the IRB approved Informed Consent form for this study.

• Subject is able to complete Quality of Life (QoL) and pain questionnaires.

• Subject is at least 21 years old.

• Subject is willing to comply and able to participate fully in, and for the full duration of, the study including follow-up requirements.

Locations
United States
Alabama
University of South Alabama
RECRUITING
Mobile
Colorado
SurgOne
ACTIVE_NOT_RECRUITING
Denver
Florida
GenesisCare
TERMINATED
Destin
Surgical Healing Arts Center
TERMINATED
Fort Myers
Kansas
St. Luke's Hospital
RECRUITING
Overland Park
Kentucky
University of Louisville
RECRUITING
Louisville
Michigan
Munson Healthcare
RECRUITING
Traverse City
New York
St. Francis Hospital
WITHDRAWN
Roslyn
Mohawk Valley Health System
RECRUITING
Utica
Texas
Houston Methodist
ACTIVE_NOT_RECRUITING
Houston
Contact Information
Primary
Melissa LaMantia
mlamantia@telabio.com
757-761-4922
Backup
Danielle Campbell
dcampbell@telabio.com
717-676-2589
Time Frame
Start Date: 2021-04-29
Estimated Completion Date: 2027-12-30
Participants
Target number of participants: 160
Treatments
Other: OviTex Reinforced Tissue Matrix
This is a single-arm study. All study subjects will receive OviTex.
Related Therapeutic Areas
Sponsors
Collaborators: MCRA
Leads: Tela Bio Inc

This content was sourced from clinicaltrials.gov